SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Inclusion Criteria:

- Male or female subjects aged ≥ 18 years and ≤ 85 years.

- Subjects with acute non-infectious anterior uveitis with onset of symptoms within the
previous 2 weeks.

- Best corrected visual acuity (BCVA) better than or equal to 35 letters in the study
eye and 65 letters in the non-study eye using ETDRS testing.

Exclusion Criteria:

- Have severe/serious ocular pathology in the study eye(s) which may preclude study
completion, in the judgement of the Investigator.

- Active intermediate or posterior uveitis in the study eye(s).

- Previous anterior uveitis episode in the study eye ≤ 4 weeks prior to screening.

- Have participated in another investigational device or drug study within 30 days prior
to screening.

- Participation in a prior ADX-102 study.